Role of stearoyl-CoA desaturase in human metabolic disease

Future Lipidology

Volumn 3, Issue 2, 2008, Pages 163-173

  Sampath, Harini ^a   Ntambi, James M ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Desaturation ratio; Hypertriglyceridemia; Insulin sensitivity; Lipid oxidation; Lipogenesis; Metabolic syndrome; Stearoyl CoA desaturase

Indexed keywords

ACYL COENZYME A DESATURASE; C REACTIVE PROTEIN; CELL NUCLEUS RECEPTOR; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PROTEIN KINASE C; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STRESS ACTIVATED PROTEIN KINASE; TROGLITAZONE;

CARDIOVASCULAR DISEASE; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; EPIDEMIC; FATTY ACID DESATURATION; FATTY LIVER; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LIPOGENESIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; WHITE ADIPOSE TISSUE;

MUS;

EID: 47249089071     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.2.163     Document Type: Review

References (94)

1. Zivkovic AM, German JB, Sanyal AJ: Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 86, 285-300 (2007).
2. Isomaa B: A major health hazard: the metabolic syndrome. Life Sci. 73, 2395-2411 (2003).
3. Grundy SM: Metabolic syndrome: a multiplex cardiovascular risk factor. J. Clin. Endocrinol. Metab. 92, 399-404 (2007).
4. Sampath H, Ntambi JM: The fate and intermediary metabolism of stearic acid. Lipids 40, 1187-1191 (2005).
5. Sampath H, Ntambi JM: Stearoyl-coenzyme A desaturase 1, sterol regulatory element binding protein-1c and peroxisome proliferator-activated receptor-α: independent and interactive roles in the regulation of lipid metabolism. Curr. Opin. Clin. Nutr. Metab. Care 9, 84-88 (2006).
6. Man WC, Miyazaki M, Chu K, Ntambi JM: Membrane topology of mouse stearoyl-CoA desaturase 1. J. Biol. Chem. 281, 1251-1260 (2006).
7. Dobrzyn A, Ntambi JM: The role of stearoyl-CoA desaturase in the control of metabolism. Prostaglandins Leukot. Essent. Fatty Acids 73, 35-41 (2005).
8. Rudel LL, Haines J, Sawyer JY, Shah R, Wilson MS, Carr TP: Hepatic origin of cholesteryl oleate in coronary artery atherosclerosis in African green monkeys. Enrichment by dietary monounsaturated fat. J. Clin. Invest. 100, 74-83 (1997).
9. -/- mice. J. Lipid Res. 48, 1122-1131 (2007).
10. Ntambi JM, Miyazaki M, Dobrzyn A: Regulation of stearoyl-CoA desaturase expression. Lipids 39, 1061-1065 (2004).
11. Miyazaki M, Ntambi JM: Role of stearoyl-coenzyme A desaturase in lipid metabolism. Prostaglandins Leukot. Essent. Fatty Acids 68, 113-121 (2003).
12. Miyazaki M, Kim YC, Ntambi JM: A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J. Lipid Res. 42, 1018-1024 (2001).
13. Miyazaki M, Kim YC, Gray-Keller MP Attie AD, Ntambi JM: The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1. J. Biol. Chem. 275, 30132-30138 (2000).
14. Miyazaki M, Dobrzyn A, Man WC et al.: Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J. Biol. Chem. 279, 25164-25171 (2004).
15. Miyazaki M, Dobrzyn A, Elias PM, Ntambi JM: Stearoyl-CoA desaturase-2 gene expression is required for lipid synthesis during early skin and liver development. Proc. Natl Acad. Sci. USA 102, 12501-12506 (2005).
16. Miyazaki M, Bruggink SM, Ntambi JM: Identification of mouse palmitoyl-coenzyme A Δ9-desaturase. J. Lipid Res. 47, 700-704 (2006).
17. Miyazaki M, Jacobson MJ, Man WC et al.: Identification and characterization of murine SCD4, a novel heart-specific stearoyl-CoA desaturase isoform regulated by leptin and dietary factors. J. Biol. Chem. 278, 33904-33911 (2003).
18. Sampath H, Ntambi JM: Polyunsaturated fatty acid regulation of genes of lipid metabolism. Annu. Rev. Nutr. 25, 317-340 (2005).
19. Dobrzyn A, Dobrzyn P, Lee SH et al.: Stearoyl-CoA desaturase-1 deficiency reduces ceramide synthesis by downregulating serine palmitoyltransferase and increasing β-oxidation in skeletal muscle. Am. J. Physiol. Endecrinol. Metab. 288, E599-E607 (2005).
20. Ntambi JM, Miyazaki M, Stoehr JP et al.: Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc. Natl Acad Sci. USA 99, 11482-11486 (2002).
21. Dobrzyn P, Dobrzyn A, Miyazaki M et al.: Stearoyl-CoA desaturase 1 deficiency increases fatty acid oxidation by activating AMP-activated protein kinase in liver. Proc. Natl Acad. Sci. USA 101, 6409-6414 (2004).
22. Miyazaki M, Flowers MT, Sampath H et al.: Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 6, 484-496 (2007).
23. Lin J, Yang R, Tarr PT et al.: Hyperlipidemic effects of dietary saturated fats mediated through PGC-1β coactivation of SREBP. Cell 120, 261-273 (2005).
24. Sampath H, Miyazaki M, Dobrzyn A, Ntambi JM: Stearoyl-CoA desaturase-1 mediates the pro-lipogenic effects of dietary saturated fat. J. Biol. Chem. 282, 2483-2493 (2007).
25. Cohen P. Miyazaki M, Socci ND et al.: Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss. Science 297, 240-243 (2002).
26. Flowers JB, Rabaglia ME, Schueler KL et al.: Loss of stearoyl-CoA desaturase-1 improves insulin sensitivity in lean mice but worsens diabetes in leptin-deficient obese mice. Diabetes 56, 1228-1239 (2007).
27. Savage DB, Petersen KF, Shulman GI: Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507-520 (2007).
28. Petersen KF, Shulman GI: Etiology of insulin resistance. Am. J. Med. 119, S10-S16 (2006).
29. Rahman SM, Dobrzyn A, Lee SH, Dobrzyn P, Miyazaki M, Ntambi JM: Stearoyl-CoA desaturase 1 deficiency increases insulin signaling and glycogen accumulation in brown adipose tissue. Am. J. Physiol. Endocrinol. Metab. 288, E381-E387 (2005).
30. Rahman SM, Dobrzyn A, Dobrzyn P, Lee SH, Miyazaki M, Ntambi JM: Stearoyl-CoA desaturase 1 deficiency elevates insulin-signaling components and down-regulates protein-tyrosine phosphatase 1B in muscle. Proc. Natl Acad. Sci. USA 100, 11110-11115 (2003).
31. Dobrzyn P, Sampath H, Dobrzyn A, Miyazaki M, Ntambi JM: Loss of stearoyl-CoA desaturase 1 inhibits fatty acid oxidation and increases glucose utilization in the heart. Am. J. Physiol. Endocrinol. Metab. 294(2), E357-E364 (2008).
32. Narayan SB, Rakheja D, Tan L, Pastor JV, Bennett MJ: CLN3P, the Battens disease protein, is a novel palmitoyl-protein Δ-9 desaturase. Ann. Neurol. 60, 570-577 (2006).
33. Georgel P, Crozat K, Lauth X et al.: A toll-like receptor 2-responsive lipid effector pathway protects mammals against skin infections with gram-positive bacteria. Infect. Immun. 73, 4512-4521 (2005).
34. Alfadley A, Al Hawsawi K, Al Aboud K: Ichthyosis follicularis: a case report and review of the literature. Pediatr. Dermatol. 20, 48-51 (2003).
35. Melhus H, Riserus U, Warensjo E et al.: A high activity index of stearoyl-CoA desaturase is associated with increased risk of fracture in men. Osteoporos. Int. DOI:10.1007/s00198-007-0521-y (2007) (Epub ahead of print).
36. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348, 1625-1638 (2003).
37. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE: Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol. Biomarkers Prev. 14, 459-466 (2005).
38. Rodriguez C, Freedland SJ, Delta A et al.: Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol. Biomarkers Prev. 16, 63-69 (2007).
39. Ceschi M, Gutzwiller F, Moch H, Eichholzer M, Probst-Hensch NM: Epidemiology and pathophysiology of obesity as cause of cancer. Swiss Med. Wkly 137, 50-56 (2007).
40. Scaglia N, Caviglia JM, Igal RA. High stearoyl-CoA desaturase protein and activity levels in simian virus 40 transformed-human lung fibroblasts. Biochim. Biophys. Acta 1687, 141-151 (2005).
41. Scaglia N, Igal RA: Stearoyl-CoA desaturase is involved in the control of proliferation, anchorage-independent growth, and survival in human transformed cells. J. Biol. Chem. 280, 25339-25349 (2005).
42. Morgan-Lappe SE, Tucker LA, Huang X et al.: Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res. 67, 4390-4398 (2007).
43. Bene H, Lasky D, Ntambi JM: Cloning and characterization of the human stearoyl-CoA desaturase gene promoter: transcriptional activation by sterol regulatory element binding protein and repression by polyunsaturated fatty acids and cholesterol. Biochem. Biophys. Res. Commun. 284, 1194-1198 (2001).
44. Zhang L, Ge L, Tran T, Stenn K, Prouty SM: Isolation and characterization of the human stearoyl-CoA desaturase gene promoter: requirement of a conserved CCAAT cis-element. Biochem. J. 357, 183-193 (2001).
45. Wang J, Yu L, Schmidt RE et al.: Characterization of HSCD5, a novel human stearoyl-CoA desaturase unique to primates. Biochem. Biophys. Res. Commun. 332, 735-742 (2005).
46. Hulver MW, Berggren JR, Carper MJ et al.: Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab. 2, 251-261 (2005).
47. Beiraghi S, Zhou M, Talmadge CB et al.: Identification and characterization of a novel gene disrupted by a pericentric inversion inv(4) (p13.1q21.1) in a family with cleft lip. Gene 309, 11-21 (2003).
48. Zhang S, Yang Y, Shi Y: Characterization of human SCD2, an oligomeric desaturase with improved stability and enzyme activity by cross-linking in intact cells. Biochem. J. 388, 135-142 (2005).
49. Warensjo E, Riserus U, Vessby B: Fatty acid composition of serum lipids predicts the development of the metabolic syndrome in men. Diabetologia 48, 1999-2005 (2005).
50. Warensjo E, Ohrvall M, Vessby B: Fatty acid composition and estimated desaturase activities are associated with obesity and lifestyle variables in men and women. Nutr. Metab. Cardiovasc. Dis. 16, 128-136 (2006).
51. Warensjo E, Ingelsson E, Lundmark P et al.: Polymorphisms in the SCD1 gene: associations with body fat distribution and insulin sensitivity. Obesity (Silver Spring) 15, 1732-1740 (2007).
52. Corpeleijn E, Feskens EJ, Jansen EH et al.: Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 49, 2392-2401 (2006).
53. Stumvoll M: Control of glycaemia: from molecules to men. Minkowski Lecture 2003. Diabetologia 47, 770-781 (2004).
54. Simon JA, Fong J, Bernert JT Jr: Serum fatty acids and blood pressure. Hypertension 27, 303-307 (1996).
55. Attie AD, Krauss RM, Gray-Keller MP et al.: Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J. Lipid Res. 43, 1899-1907 (2002).
56. Paillard F, Catheline D, Duff FL, et al.: Plasma palmitoleic acid, a product of stearoyl-CoA desaturase activity, is an independent marker of triglyceridemia and abdominal adiposity. Nutr. Metab. Cardiovasc. Dis. DOI: 10.1016/j.numecd.2007.02.017 (2007) (Epub ahead of print).
57. Sjogren P, Sierra-Johnson J, Gertow K. et al.: Fatty add desaturases in human adipose tissue: relationships between gene expression, desaturation indexes and insulin resistance. Diabetologia 51(2), 328-335 (2008).
58. Despres JP: Cardiovascular disease under the influence of excess visceral fat. Crit. Pathw. Cardiol. 6, 51-59 (2007).
59. Kelley DE, Williams KV, Price JC, McKolanis TM, Goodpaster BH, Thaete FL: Plasma fatty acids, adiposity, and variance of skeletal muscle insulin resistance in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 86, 5412-5419 (2001).
60. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48, 839-847 (1999).
61. Iannucci CV, Capoccia D, Calabria M, Leonetti F: Metabolic syndrome and adipose tissue: new clinical aspects and therapeutic targets. Curr. Pharm. Des. 13, 2148-2168 (2007).
62. Tchernof A: Visceral adipocytes and the metabolic syndrome. Nutr. Rev. 65, S24-S29 (2007).
63. Mangravite LM, Dawson K, Davis RR, Gregg JP, Krauss RM: Fatty acid desaturase regulation in adipose tissue by dietary composition is independent of weight low and is correlated with the plasma triacylglycerol response. Am. J. Clin. Nutr. 86, 759-767 (2007).
64. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM et al.: PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15, 5336-5348 (1996).
65. Frohnert BI, Hui TY, Bernlohr DA: Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J. Biol. Chem. 274, 3970-3977 (1999).
66. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA: A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8, 1122-1128 (2002).
67. Kim YC, Gomez FE, Fox BG, Ntambi JM: Differential regulation of the stearoyl-CoA desaturase genes by thiazolidinediones in 3T3-L1 adipocytes. J. Lipid Res. 41, 1310-1316 (2000).
68. Kakuma T, Lee Y, Unger RH: Effects of leptin, troglitazone, and dietary fat on stearoyl CoA desaturase. Biochem. Biophys. Res. Commun. 297, 1259-1263 (2002).
69. Toyama T, Kudo N, Hibino Y, Mitsumoto A, Nishikawa M, Kawashima Y: Effects of pioglitazone on stearoyl-CoA desaturase in obese Zucker falfa rats. J. Pharmacol. Sci. 104, 137-145 (2007).
70. Way JM, Harrington WW, Brown KK et al.: Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142, 1269-1277 (2001).
71. Singh Ahuja H, Liu S, Crombie DL et al.: Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol. Pharmacol. 59, 765-773 (2001).
72. Riserus U, Tan GD, Fielding BA et al.: Rosiglitazone increases indexes of stearoyl-CoA desaturase activity in humans: link to insulin sensitization and the role of dominant-negative mutation in peroxisome proliferator-activated receptor-γ. Diabetes 54, 1379-1384 (2005).
73. Boden G, Lebed B, Schatz M, Homko C, Lemieux S: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50, 1612-1617 (2001).
74. Bachmann OP, Dahl DB, Brechtel K et al.: Effects of intravenous and dietary lipid challenge on intramyocellular lipid content and the relation with insulin sensitivity in humans. Diabetes 50, 2579-2584 (2001).
75. Goodpaster BH, Thaete FL, Kelley DE: Thigh adipose tissue distribution is associated with insulin resistance in obesity and in Type 2 diabetes mellitus. Am. J. Clin. Nutr. 71, 885-892 (2000).
76. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46, 1579-1585 (1997).
77. Krssak M, Falk Petersen K, Dressner A et al.: Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42, 113-116 (1999).
78. Yu C, Chen Y, Cline GW et al.: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230-50236 (2002).
79. Chavez JA, Summers SA: Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch. Biochem. Biophys. 419, 101-109 (2003).
80. Itani SI, Ruderman NB, Schmieder F, Boden G: Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IκB-α. Diabetes 51, 2005-2011 (2002).
81. Ropelle ER, Pauli JR, Prada PO et al.: Reversal of diet-induced insulin resistance with a single bout of exercise in the rat: the role of PTP1B and IRS-1 serine phosphorylation. J. Physiol. 577, 997-1007 (2006).
82. Hirosumi J, Tunanan G, Chang L et al.: A central role for JNK in obesity and insulin resistance. Nature 420, 333-336 (2002).
83. Yuan M, Konstantopoulos N, Lee J et al.: Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673-1677 (2001).
84. Goodpaster BH, He J, Watkins S, Kelley DE: Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J. Clin. Endocrinol. Metab. 86, 5755-5761 (2001).
85. Schenk S, Horowitz JF: Acute exercise increases triglyceride synthesis in skeletal muscle and prevents fatty acid-induced insulin resistance. J. Clin. Invest. 117, 1690-1698 (2007).
86. Richter EA, Mikines KJ, Galbo H, Kiens B: Effect of exercise on insulin action in human skeletal muscle. J. Appl. Physiol. 66, 876-885 (1989).
87. Perseghin G, Price TB, Petersen KF et al.: Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N. Engl. J. Med. 335, 1357-1362 (1996).
88. Devlin JT, Horton ES: Effects of prior high-intensity exercise on glucose metabolism in normal and insulin-resistant men. Diabetes 34, 973-979 (1985).
89. Pinnamaneni SK, Southgate RJ, Febbraio MA, Watt MJ: Stearoyl CaA desaturase 1 is elevated in obesity but protects against fatty acid-induced skeletal muscle insulin resistance in vitro. Diabetologia 49, 3027-3037 (2006).
90. Gutierrez-Juarez R, Pocai A, Mulas C et al.: Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance. J. Clin. Invest. 116, 1686-1695 (2006).
91. Le KA, Faeh D, Stettler R et al.: Effects of four-week high-fructose diet on gene expression in skeletal muscle of healthy men. Diabetes Metab. 34, 82-85 (2008).
92. Puigserver P: Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-α. Int. J. Obes. (Lond.) 29(Suppl. 1), S5-S9 (2005).
93. Petersson H, Basu S, Cederholm T, Riserus U: Serum fatty acid composition and indices of stearoyl-CoA desaturase activity are associated with systemic inflammation: longitudinal analyses in middle-aged men. Br. J. Nutr. 6, 1-4 (2007).
94. Ndumele CE, Pradhan AD, Ridker PM: Interrelationships between inflammation, C-reactive protein, and insulin resistance. J. Cardiometab. Syndr. 1, 190-196 (2006).